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Abstract
Background: The resection of large oropharyngeal tumors traditionally involves a lip-splitting mandibulotomy for
adequate margin visualization and free flap reconstruction of the surgical defect. Transoral robotic surgery (TORS)
has emerged as a technique that can resect large and complex oropharyngeal tumors, avoiding a lip-splitting
approach. The aim of this study is to compare the lip-splitting mandibulotomy approach versus TORS for the
management of advanced stage oropharyngeal carcinomas.
Methods: Prospectively collected data from 18 patients with advanced stage oropharyngeal squamous cell
carcinoma (OPSCC) who received TORS with radial forearm free flap reconstruction (RFFF) was compared to a
matched cohort of 39 patients who received a lip-splitting mandibulotomy and RFFF. Patients were matched for
stage, p16 positivity, smoking, age and gender. Length of hospital stay (LOHS), tracheostomy decanulation time,
operative time, surgical margin status, and post-operative complications were compared between groups.
Results: Patients who received TORS with RFFF had a significantly lower mean LOHS, compared to patients who
were treated by lip-splitting mandibulotomy and RFFF (14.4 vs 19.7 days, p = 0.03). No significant differences
were seen between groups in terms of operative time, tracheostomy decannulation time, margin positivity and
post-operative complications.
Conclusion: TORS with radial forearm free flap reconstruction is a safe, effective and cost-saving alternative to
the lip-splitting mandibulotomy approach for the treatment of advanced stage OPSCC.
Keywords: Oropharyngeal cancer, Transoral robotic surgery, Mandibulotomy, Radial forearm free flap, Human
papillomavirus
Background
Oropharyngeal squamous cell carcinoma (OPSCC) is
caused by tobacco smoking, alcohol and oncogenic hu-
man papillomavirus (HPV). Over the past decade, the in-
cidence of HPV-related OPSCC has been rising worldwide
[1–7]. When compared to non-HPV related OPSCC,
HPV-OPSCC is molecularly distinct and patients with
these tumors have improved survival outcomes regardless
of treatment modality [8–20].
The treatment of advanced stage OPSCC has been a
subject of controversy in recent years, as comparable
survival outcomes can be achieved with either chemora-
diation or primary surgery for HPV-positive tumors. The
increasing use of transoral robotic surgery (TORS) since
its FDA approval in 2009 has paralleled a paradigm shift
towards primary surgical treatment of OPSCC [9, 21–25].
Several reports have shown favorable oncologic outcomes
with TORS, while minimizing morbidity and disfigurement
associated with mandibulotomy approaches [26–28]. In
comparison to chemoradiation, treatment of OPSCC
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patients with TORS has also been shown to result in better
functional outcomes and decreased cost [21, 22, 29–31].
TORS has proven efficacy in the resection of small pri-
mary (T1 and T2) oropharyngeal tumors, however, with
increasing use, the applications of this tool has expanded.
Recent reports from several independent centers have de-
scribed the use of TORS for the resection of more ad-
vanced oropharyngeal cancers, those requiring free flap
reconstruction [32–40], in cases traditionally approached
by lip-splitting mandibulotomy. TORS with free flap re-
construction (TORS-FF) is thought to be a safe and less
invasive alternative to the mandibulotomy approach.
However, the literature describing TORS-FF is limited to
case reports and small case series with no comparative
group.
The goal of this study was to compare TORS to the
lip-splitting mandibulotomy approach in the primary
surgical treatment of advanced stage OPSCC in patients
with planned free flap reconstruction.
Methods
Patient data
All OPSCC patients who received TORS and radial fore-
arm free flap reconstruction (RFFF) from May 2015-July
2016 or lip-splitting mandibulotomy with RFFF from
January 2006-July 2016 at the University of Alberta were
included in the study. Patient demographics were obtained
from prospectively collected databases through the Al-
berta Cancer Registry, with details verified in paper charts
and electronic medical records. Smoking status was de-
fined as having a greater than 10 pack year tobacco smok-
ing history [11]. P16 status was obtained though standard
pathology for TORS patients and from tissues microarray
data previously reported for mandibulotomy patients [9].
Operative time was obtained from standardized nursing
and anesthesia records, calculated from induction of
general anesthesia to surgical case completion. Surgical
margin status was obtained from final post-operative
pathology. Length of hospital stay was calculated from
the start of surgical procedure to date of discharge
based on standardized discharge criteria according to
head and neck care protocols [41].
Transoral robotic surgery
All patients received a prophylactic tracheostomy for air-
way safety [32, 33, 35, 38, 42] as well as a nasogastric
tube placement. TORS was performed using the da Vinci
S Surgical System (Intuitive Surgical, Sunnyvale, CA) at
the beginning of the procedure with the exception of
three patients who had ipsilateral N3 nodal disease. In
N3 patients, the neck dissection was completed for safe
exposure of the carotid artery, followed by TORS of the
primary tumor. Oropharyngeal exposure was obtained
using Crowe-Davis or Feyh-Kastenbauer mouth retractor
and visualized with a 0- or 30- degree endoscope. TORS
resection was performed using monopolar cautery and a
Maryland dissector. Intraoperative frozen sections were
taken from the ablative defect.
Free flap reconstruction of TORS defect
Once the size of the oropharyngeal defect was known an ap-
propriate sized free flap was elevated in the standard fashion.
The radial forearm free flap was used for its versatility in
reconstructing of multiple defects of the oropharynx includ-
ing fasciocutaneous re-lining, soft palate repair as well as
beaver-tail modifications for functional base of tongue re-
construction [43–46]. An analysis of the tumor extirpation
defect was done based on subsite(s) resected, including per-
cent resected of the soft palate, lateral pharyngeal wall/tonsil
and base of tongue. If > 50% of the soft palate was resected
functional soft palate reconstruction was initiated [45], and
if > 50% of the base of tongue is resected a beavertail modi-
fied free flap was utilized [44]. Two patients had >50% of
total tongue base resected and 1 patient had > 50% of soft
palate resected. These oropharyngeal reconstructive tech-
niques are comprehensively described elsewhere [46].
Trans-cervical and pharyngeal accesses were used for in-
ferior repair of the pharynx and inset of the free flap. The
ipsilateral suprahyoid muscles and nerves were preserved
whenever possible but the ipsilateral hypoglossal and lin-
gual nerves can be transected to provide wider access. The
lingual nerve was transected and re-anastomosed following
inset in 3 patients. These nerves should be reconstructed
primarily or cable grafted, to limited the impact on post-
operative speech and swallowing function [47].
The inferior portion of the flap was inset initially trans-
cervically, though the lateral pharyngotomy The remain-
der of the flap was then inset via the oral cavity through a
transoral approach. The robot was not used to inset any
portion of the flap. Microvascular anastomosis to recipient
vessels in the neck were performed after the inset of the
flap was complete.
Cost comparison
Surgical instrument costs were determined from nursing
case logs for instrument use standard to TORS vs man-
dibulotomy approaches for oropharyngeal cancer resec-
tions. Physician billing costs were estimated from
standard surgeon and anesthesia billings according to
the Alberta Health Services Schedule of Medical Benefits
(http://www.health.alberta.ca/professionals/SOMB.html).
Hospital stay cost estimates were obtained from Alberta
Health Services cost estimates (http://obrieniph.ucalgar-
y.ca/health-econ/research-reports).
Data analysis
Patients who received a lip-splitting mandibulotomy and
RFFF were systematically matched to patients who
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received TORS with RFFF. Patients were fist matched by
exact T stage and p16 status, followed by closest matching
possible for smoking status, age, gender and nodal stage.
Statistical comparisons of group variables were performed
in SPSS version 22 (Chicago, IL, USA) using Chi-Square
or Mann Whitney U tests where appropriate.
Results
Patient characteristics
From May 2015 to July 2016, 38 patients received TORS
at the University of Alberta, of which 18 received a ra-
dial forearm free flap (RFFF) reconstruction and were in-
cluded in this study. These patients were compared to a
historical cohort of 76 OPSCC patients who were treated
with primary surgery using a lip-splitting mandibulotomy
approach and RFFF (Fig. 1). Patients met criteria for free
flap reconstruction of TORS defects if they had one or
more of the following adverse features as previously de-
scribed [37]. 1) >50% palate defect, 2) pharyngo-cervical
communication and/or 3) exposed pharyngeal internal ca-
rotid artery. All patients in the TORS or mandibulotomy
cohorts met the above criteria (all class III/IV) and there-
fore met indications for free flap reconstruction.
Twenty-nine patients who received a mandibulotomy
were identically matched to the TORS patients for p16
positivity, smoking and T-stage, and closely matched for
age (+/-10 years), sex, tumor subsite and nodal status
(Fig. 1 and Table 1). In comparing matched patients who
received TORS + RFFF vs mandibulotomy + RFFF, there
were no statistically significant differences between these
groups with regard to age, sex, p16 positivity, primary
tumor subsite, T-stage and N-stage (Table 1).
Operative outcomes
No TORS cases were converted to open, lip-splitting
mandibulotomy. Negative intra-operative frozen sections
were obtained for all patients treated with TORS-FF.
Two (6.9%) patients treated with a lip-splitting approach
had positive margins reported on post-operative path-
ology. The operative time was similar for patients treated
with a TORS (15.0 h) vs mandibulotomy (15.5 h) ap-
proach (Table 2).
Post-operative outcomes
Patients treated with TORS had a significantly shorter
length of hospital stay compared to mandibulotomy pa-
tients (14.4 vs 19.7 days, p = 0.03). No significant differences
were seen between these groups in terms of post-operative
intensive care unit stay, time to decannulation or gastros-
tomy tube dependency (Table 2).
Adverse events
Although valid statistical comparisons cannot be made
between groups, patients treated with TORS experienced
fewer complications overall (Table 3). Patients had compar-
able numbers of post-operative hematoma, abscess, chyle
leak and blood loss requiring post-operative packed red
blood cell transfusion. In the mandibulotomy group how-
ever, three patients experienced airway obstruction post-
tracheostomy decannulation (requiring re-cannulation),
Fig. 1 Summary of oropharyngeal cancer patients selected for inclusion in this study
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which did not occur in TORS patients. There were no free
flap failures in either group. No intraoperative or peri-
operative fatalities occurred.
Cost comparison
Comparison of cost estimates for TORS vs mandibulot-
omy approaches showed reduced cost of surgical instru-
ments, physician billings and hospital stay associated with
TORS (Table 4). Overall, the TORS approach is estimated
to result in a cost reduction of $ 6409.98 per case.
Discussion
TORS has been mainly used for the resection of small
(T1 or T2) OPSCCs with the resulting defect left to heal
secondarily or by primary closure. Recently, a number of
reports have described the use of TORS for the resection
of larger tumors, traditionally approached by lip-splitting
mandibulotomy followed with free flap reconstruction
[32–40]. To date, this study reports outcomes on the lar-
gest cohort of OPSCC patients treated with TORS and
free flap reconstruction and provides the best available
evidence for this approach.
TORS with free flap reconstruction is a recent surgical
advancement with literature describing this procedure
limited to case reports and small case series ranging
from one to eleven patients [32–40, 42]. The most com-
mon post-TORS free flap reported in the literature is the
radial forearm (N = 37), followed by anterolateral thigh
Table 1 Matched demographic, exposure and tumor
characteristics of patients with oropharyngeal squamous cell
carcinoma in this study
Variable TORS (n = 18) Mandibulotomy (n = 29) P
Age, years 59.6 57.6 0.69
Sex, % M 66.7 80.7 0.31
Smoking status (%) 10 (55.5) 17 (58.6) 0.67
P16 positivity (%) 16 (88.9) 25 (93.1) 0.61
Tumor subsite (%)
Tonsil 13 (72.2) 16 (55.2) 0.36
Base of Tongue 5 (27.8) 13 (44.8)
Pathologic stage (%)
T1 5 (27.8) 7 (26.9) 0.96
T2 10 (55.5) 17 (58.6)
T3 3 (16.7) 5 (19.2)
N0 1 (5.6) 1 (3.8)
N1 1 (5.6) 3 (11.5) 0.68
N2 13 (72.2) 23 (79.3.)
N3 3 (16.7) 2 (7.7)
Table 2 Outcomes of oropharyngeal cancer patients treated
with TORS vs mandibulotomy and radial forearm free flap
reconstruction
Outcome TORS Mandibulotomy P
Operative time 15.0 15.5 0.77
LOHS (days) 14.4 19.7 0.03
Positive margins (%) 0 6.9 0.52
ICU stay (days) 1.9 2.0 0.76
Decannulation (days) 7.5 9.1 0.97
G-tube 1 month (%)a 16.6 13.7 0.68
G-tube 12 months (%)b 5.5 13.7 0.50
ICU intensive care unit; LOHS length of hospital stay
aG-tube dependency and readmissions to hospital reported for up to
30 days post-discharge
b1 year g-tube rates not available for all given the study end date (July 2016)
but is available to all patients who did receive a g-tube
Table 3 Adverse events in patients receiving TORS vs




Chyle leak 1 1
Blood transfusiona 3 5
Airway obstructionb 0 3




No significant differences were seen between groups
aBlood transfusions were measured as either intra-operative or post-operatively
up to the point of discharge from hospital
bAirway obstruction post-tracheostomy decannulation requiring
further intervention
Table 4 Cost comparison of TORS vs mandibulotomy and radial
forearm free flap reconstruction
Items TORS Mandibulotomy
Surgical instrumentsa
Robotic arms (x2) $ 1109.72 -
Robotic drapes $ 469.67 -
Plates and screws - $ 1072.58
Saw blades and tubing - $ 693.53
Physician billingsb $ 181.19 $ 235.25
Surgical ward stay (mean) $ 16,761.6 $ 22,930.8
Totals $ 18, 522.18 $ 24,932.16
Cost shown per case in Canadian dollars. Operating time and intensive care
unit stays were not statistically different between both groups and is not
shown in the analysis
aOnly surgical items that are different between both cases are included. Cost
of non-disposable items such as the Da Vinci robotic system (purchased prior
to the study for non-head and neck robotic surgery) and drills/saws are
not included
bIncludes only billings that are different between both cases, for anesthesia
and surgeon codes as per the 2014–2016 Alberta Health Services Schedule of
Medical Benefits
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(N = 5) and vastus lateralis (N = 1). The radial forearm
free flap is generally the first option for oropharyngeal
reconstruction [44, 45, 48–52] unless it is contraindi-
cated. Given the pliability of this flap, it is an excellent
option for reconstruction of TORS oropharyngeal de-
fects, whereby insetting is challenging with more limited
access.
The overall surgical time of this approach was compar-
able to matched mandibulotomy cases (15.0 vs 15.5 h, p =
0.77) even though TORS resection of the primary tumor
may result in a more challenging free flap inset. TORS-FF
operative time reported in this study was also similar
to data in the literature, ranging from 12.25 to 17.5 h
[38, 40]. In our experience, additional time is required
for TORS set-up and free flap insetting is counter balanced
by avoiding a mandibulotomy and plate reconstruction.
Traditionally a lip-splitting mandibulotomy was re-
quired for oncologic resection of oropharyngeal tumors
followed by free tissue reconstruction in most cases.
This time proven approach provides safe and effective
surgical access, but is associated with delayed recovery
of oral function and obvious facial scarring [34, 53].
TORS offers the advantage of superb visualization as
demonstrated by the reduced positive margin rate and
precise instrumentation to perform large oropharyngeal
resections in a less invasive and cosmetically superior
fashion. In our case-matched cohort, patients who re-
ceived TORS-FF were discharged from hospital an aver-
age of 5.3 days earlier than patients who were treated
with mandibulotomy. Reasons for decreased LOHS in
TORS patients could not be unequivocally ascertained
but these data are consistent with the literature [33]. We
hypothesize that TORS-FF patients meet discharge cri-
teria earlier due to a number of factors such as edema,
pain control and swallowing but this requires additional
investigation. This reduction in LOHS may also result in
significant health care cost savings.
Recent studies suggest TORS may provide superior
swallowing outcomes for patients with OPSCC. A review
of the US Nationwide Inpatient Sample reported a sig-
nificant decrease in g-tube rates (0% vs 19%) in OPSCC
patients treated with TORS vs other surgical approaches
[30]. Sharma et al. reported lower g-tube rates in OPSCC
patients treated with TORS vs a T-stage matched cohort
treated with chemoradiotherapy [31]. In case series of pa-
tients receiving TORS-FF for OPSCC, one group reported
44% (4/9) of patients to be g-tube dependent at 1 year
[32], while another group reported only 9% (1/11) patients
temporarily required a g-tube [37]. Our TORF-FF patients
had comparable rates of g-tube dependency (16.6%) to pa-
tients who received a mandibulotomy. We are performing
further follow-up assessments of function in a larger
group of patients receiving TORS-FF to evaluate the ef-
fects of surgery on swallowing.
A number of studies have demonstrated lower positive
margin resection rates with TORS vs other surgical ap-
proaches, which potentially translates into improved local
disease control [21, 22, 26, 27] and de-intensification of
adjunctive treatment. Two large multi-institutional studies
(N = 177 and N = 410) estimated positive margins rates
from TORS to be 4.3 to 9.9% with close margins (1–
5 mm) in 21.0% of patients receiving TORS [26, 27]. Our
study demonstrated low rates of positive margins in
TORS-FF (0%) and mandibulotomy patients (6.9%). Our
TORS approach aims to take ≥1 cm margins, which can
be performed safely in the setting of planned free flap re-
construction. Although long-term follow-up would be re-
quired to verify the oncologic outcomes associated with
the TORS-FF, this data suggests at least equivalent local
disease control can be achieved with this approach.
A number of limitations should be considered when
interpreting results from this study. Bias between com-
parative groups was minimized using a case-control
study design, however, data from the lip-splitting mandi-
bulotomy cohort was obtained retrospectively. Cost
comparisons are based on Alberta Health Services mean
costing data and only includes estimated costs associated
with the surgical procedues and hospital stay. Additional
costs such as patient/caregiver travel, parking, childcare
and loss of employment could not be accurately calculated
in this study and are therefore not included. Some con-
founders may have influenced the LOHS between groups,
given the implementation of head and neck post-operative
care pathways in 2015. As the majority of mandibulotomy
patients being compared received post-operative care
prior to 2015, the LOHS in this group could be lower. In
the mandibulotomy patients who were treated within the
formally implemented care pathway the mean LOHS was
16 days, still higher than TORS patients. In addition, this
study was performed in a single centre with a high-
volume experience in head and neck oncologic and sur-
gery and reconstruction. Further prospective and multi-
centre studies are suggested to validate our findings.
Conclusion
TORS with radial forearm free flap reconstruction is a
safe, effective and potentially cost-saving alternative to
the lip-splitting mandibulotomy approach for the treat-
ment of advanced stage OPSCC.
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